Pedro Berraondo

57PUBLICATIONS
166CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (57)

|Sep 07, 2026
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.

|Aug 25, 2026
CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells.

|Aug 06, 2026
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

|Dec 02, 2025
Facts and Hopes in Harnessing Macrophage-Mediated Antibody-Dependent Cellular Phagocytosis for Cancer Immunotherapy.

Maria Armero, Manuel Smolkin, Mario Garcia-Dominguez

|Jun 24, 2025
The long-lasting expression of recombinant artLCMV following intraperitoneal administration exerts potent antitumor effects on tumor models of peritoneal carcinomatosis.

Celia Gomar, Aline Risson, Leire Arrizabalaga

|Jun 10, 2025
Combining local cytokine delivery and systemic immunization with recombinant artLCMV boosts antitumor efficacy in several preclinical tumor models.

Kimberly Pojar, Diana Reckendorfer, Judith Strauss

Pageof 10

Frequent Collaborators

28 joint publications

Ignacio Melero

13 joint publications

Álvaro Teijeira

9 joint publications

Iñaki Eguren-Santamaria

9 joint publications

Carlos Luri-Rey